Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Blood
Timothy HughesJohn M Goldman

Abstract

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the total leukemiacell mass and the degree to which BCR-ABL transcripts are reduced by therapy correlates with progression-free survival. Because a rising level of BCR-ABL is an early indication of loss of response and thus the need to reassess therapeutic strategy, regular molecular monitoring of individual patients is clearly desirable. Here we summarize the results of a consensus meeting that took place at the National Institutes of Health (NIH) in Bethesda in October 2005. We make suggestions for (1) harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR-ABL transcript levels on an internationally agreed scale; (2) using serial RQ-PCR results rather than bone marrow cytogenetics or fluorescence in situ hybridization (FISH) for the BCR-ABL gene to monitor individual patients responding to treatmen...Continue Reading

References

Apr 29, 1989·Lancet·G J MorganC R Bartram
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·E S KawasakiF P McCormick
May 1, 1994·British Journal of Haematology·N C CrossJ M Goldman
May 26, 1999·The New England Journal of Medicine·L ZhangD D Ho
Mar 29, 2002·Acta Haematologica·Jaspal KaedaJohn M Goldman
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sergei RoumiantsevRichard A Van Etten
May 30, 2003·The New England Journal of Medicine·Catherine Roche-LestienneClaude Preudhomme
Jun 5, 2003·Seminars in Hematology·Tim Hughes, Susan Branford
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Jan 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Haifa-Kathrin Al-AliMichael Werner Nikolaus Deininger
Apr 27, 2004·Clinical Chemistry·Simona SoveriniUNKNOWN European LeukemiaNet-6th Framework Program of the European Community
Jun 5, 2004·Genomics·Jerald P RadichPeter S Linsley

❮ Previous
Next ❯

Citations

Oct 1, 1991·Human Genetics·U KlemmW Engel
Oct 29, 2013·Annals of Hematology·Lida KalmantiUNKNOWN Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)
Oct 12, 2011·International Journal of Clinical Oncology·Chikashi YoshidaHisashi Sakamaki
Oct 2, 2013·Wiener medizinische Wochenschrift·Thomas LionGünther Gastl
May 7, 2011·Targeted Oncology·Shin Ogita, Patricia Lorusso
Apr 1, 2008·Current Hematologic Malignancy Reports·Giuseppe SaglioDaniela Cilloni
Apr 1, 2008·Current Hematologic Malignancy Reports·Paul La Rosée, Andreas Hochhaus
Apr 29, 2010·Current Hematologic Malignancy Reports·Maxim Norkin, Charles A Schiffer
Mar 2, 2011·Current Hematologic Malignancy Reports·Susan Branford, Jodi Prime
Mar 8, 2012·Current Hematologic Malignancy Reports·Meinolf SuttorpFrederic Millot
Mar 17, 2012·Current Hematologic Malignancy Reports·Susanne Saussele, Markus Pfirrmann
Sep 1, 2006·Current Hematologic Malignancy Reports·Vivian G Oehler, Jerald P Radich
Sep 1, 2006·Current Hematologic Malignancy Reports·Corey Cutler, Joseph H Antin
Jun 7, 2012·Current Oncology Reports·Theresa Liu-DumlaoFarhad Ravandi
Dec 23, 2008·International Journal of Hematology·Wing Y AuJianxiang Wang
Apr 4, 2009·International Journal of Hematology·Masahide YamamotoHisashi Sakamaki
Aug 28, 2009·Leukemia·M C MüllerA Hochhaus
Sep 17, 2010·Leukemia·D M RossJ V Melo
Jun 20, 2008·Nature Reviews. Cancer·Chandan Kumar-SinhaArul M Chinnaiyan
Jul 25, 2012·Nature Reviews. Cancer·Thomas O'HareMichael W Deininger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.